Treatment of cutaneous human papilloma virus, poxvirus and Herpes simple virus infections with topical cidofovir in HIV positive patients;Traitement par cidofovir topique d'infections cutanées à papillomavirus humain, poxvirus et Herpes simplex virus chez des malades séropositifs pour le VIH

Annales de Dermatologie et de Venereologie

Volumn 131, Issue 5, 2004, Pages 445-449

  Toutous Trellu, L ^a   Hirschel, B ^a   Piguet, V ^a   Schiffer, V ^a   Saurat, J H ^a   Pechere, M ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CIDOFOVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONDYLOMA; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; GENITAL HERPES; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; MALE; MOLLUSCUM CONTAGIOSUM; POXVIRUS INFECTION; RECURRENT DISEASE; RELAPSE; REMISSION; RETINITIS; SKIN INFECTION; SKIN INFLAMMATION; SKIN MANIFESTATION; VERRUCA PLANA JUVENILIS; VERRUCA VULGARIS; VIRUS INFECTION;

EID: 2942731400     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0151-9638(04)93637-X     Document Type: Article

References (20)

1. Calista D. Topical cidofovir for severe cutaneous human papillomavirus and molluscum contagiosum infections in patients with HIV/AIDS. A pilot study. J Eur Acad Dermatol Venereol 2000;14:484-8.
2. Lalezari J, Schaker T, Feinberg J, Gathe J, Lee S, Cheung T et al. A randomized, double-bind, placebo controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis 1997;176:892-8.
3. Safrin S, Cherrington J, Jaffe HS. Clinical uses of topical cidofovir. Rev Med Virol 1997;7:145-56.
4. Sacks SL, Shafran SD, Diaz-Mitoma F, Trottier S, Sibbald RG, Hugues A et al. A multicenter phase 1/11 dose escalation study of single-dose cidofovir gel for treatment of recurrent genital herpes. Antimicrob Agents Chemother 1998;42:2996-9.
5. Matteelli A, Beltrame A, Graifemberghi S, Forleo MA, Guletta M, Ciravolo G et al. Efficacy and tolerability of topical 1 p. 100 cidofovir cream for the treatment of external anogenital warts in HIV-infected persons. Sex Transm Dis 2001;28:343-6.
6. Davies EG, Thrasher A, Lacey K, Harper J. Topical cidofovir for severe molluscum contagiosum. Lancet 1999;353:2042.
7. Descamps V, Duval X, Grossin M, Crickx B, Leport C. Topical cidofovir for bowenoid papulosis in an HIV-infected patient. Br J Dermatol 2001;144:642-3.
8. Zabawski EJ, Sands B, Goetz D, Naylor M, Cockerell CJ. Treatment of verruca vulgaris with topical cidofovir. JAMA 1997;278:1236.
9. Davis MD, Gostout BS, McGovern RM, Persing DH, Schut RL, Pittelkow MR. Large plantar wart caused by human papillomavirus-66 and resolution by topical cidofovir therapy. J Am Acad Dermatol 2000;43:340-3.
10. Calista D. Topical cidofovir for erythroplasia of Queyrat of the glans penis. Br J Dermatol 2002;147:385-410.
11. Jabs DA, Enger C, Forman M, Dunn JP. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. Antimicrobial Agents Chemotherapy 1998;42:2240-4.
12. Bienvenu B, Martinez F, Deverjie A, Rybojad M, Rivet J, Bellenger P et al. Topical use of cidofovir induced acute renal failure. Transplantation 2002;73:661-2.
13. Zabawski EJ Jr, Cockerell CJ. Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects. J Am Acad Dermatol 1998;39:741-5.
14. Duan J, Paris W, De Marte J, Roopchand D, Fleet TL. Cordingley MG. Topical effects of cidofovir on cutaneous rabbit warts: treatment regimen and inoculum dependence. Antiviral research 2000;46:135-44.
15. Preiser W, Kapur N, Snoeck R, Groves RW, Brink NS. No apparent effect of cidofovir in epidermodysplasia verruciformis. J Clinical Virol 2000;16:55-7.
16. Santoyo S, Ga de Jalon E, Ygartua P, Renedo MJ, Blanco-Prieto M. Optimization of topical cidofovir penetration using microparticles. Int J Pharm 2002;242:107-13.
17. Pechère M, Wunderli W, Trellu-Toutous L, Harms M, Saurat JH, Krischer J. Treatment of acyclovir-resistant herpetic ulceration with topical foscarnet and antiviral sensitivity analysis. Dermatology 1998;197:278-80.
18. Piret J, Lamontagne J, Desormeaux A, Bergeron MG. Efficacy of gel formulations containing foscarnet, alone or combined with sodium lauryl sulfate, against establishment and reactivation of latent herpes simplex virus type 1. Antimicrob Agents Chemother 2001;45:1030-6.
19. Snoeck R, Andrei G, Gerard M, Silverman A, Hedderman A, Balzari J et al. Successful treatment of progressive mucocutaneous infection due to acyclovir and foscarnet resistant herpes simplex virus with (S)-1- (3-hydroxy-2- phosphonylmethoxypropyl) cytosine. Clin Infect Dis 1994;18: 570-8.
20. Javaly K, Wohlfeiler M, Kalayjian R, Klein T, Bryson Y, Grafford K et al. Treatment of mucocutaneous herpes simplex virus infections unresponsive to acyclovir with topical foscarnet cream in AIDS patients: a phase I/II study. J Acquir Immune Defic Syndr 1999;21:301-6.